Prostate cancer ranks the 3d or 4th position in the world’s incidence rate of malignant neoplasms, more than 600 thousand cases per year.In the USA, it is the first most frequently diagnosed among cancer diseases – more than 200 thousand patients per year. In Europe it is the first of second most frequently diagnosed in men (more than 200 thousands of patients per year)

«Prosta-test» is designed for noninvasive prostate cancer diagnostics by determinants of PCA3 gene expression level by reverse transcription followed by quantitative polymerase chain reaction (PCR).

Material for PCR – human RNA samples derived from fresh or fixed in the medium in order to stabilize and preserve urine RNA obtained after digital rectal examination (DRE) of the prostate, thus achieving noninvasiveness.

The result of “Prosta-test” expressed quantitatively indicates the risk of prostate cancer presence and may serve as an additional criterion for the first or subsequent biopsy appointment along with the measurement of the PSA level in the blood, ultrasonography (TRUS), MRI, CT and digital rectal examination (DRE).